{"id":"ritonavir-heat-stable","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"10-20","effect":"Taste perversion"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"15-30","effect":"Lipid abnormalities (elevated triglycerides and cholesterol)"},{"rate":"5-15","effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ritonavir binds to and inhibits HIV protease, an enzyme essential for processing viral precursor proteins into functional structural and enzymatic proteins. This prevents the formation of mature, infectious viral particles. The heat-stable formulation improves stability and reduces refrigeration requirements compared to earlier liquid formulations.","oneSentence":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:17.703Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination with other antiretroviral agents)"},{"name":"Pharmacokinetic booster for other protease inhibitors"}]},"trialDetails":[{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT01172535","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"HIV","enrollment":97},{"nctId":"NCT01307124","phase":"PHASE3","title":"Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-03","conditions":"HIV-infected Children","enrollment":199},{"nctId":"NCT01332227","phase":"PHASE4","title":"Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-10","conditions":"HIV, Combination Therapy","enrollment":132},{"nctId":"NCT00985543","phase":"PHASE1","title":"Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-10","conditions":"Acquired Immunodeficiency Syndrome","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Norvir"],"phase":"marketed","status":"active","brandName":"Ritonavir (heat-stable)","genericName":"Ritonavir (heat-stable)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection (in combination with other antiretroviral agents), Pharmacokinetic booster for other protease inhibitors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}